Compare Stocks: CNTB, GLSI, IVVD, and LXEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.09 +0.5%	$2.02	$1.05 ▼ $3.82	$68.32M	-0.23	493,671 shs	659,250 shs
GLSI Greenwich LifeSciences	$18.72 +2.7%	$15.84	$7.78 ▼ $34.10	$274.81M	1.47	217,639 shs	31,492 shs
IVVD Invivyd	$0.97 +3.5%	$0.78	$0.53 ▼ $3.07	$287.98M	0.81	3.76 million shs	3.73 million shs
LXEO Lexeo Therapeutics	$3.18 -3.8%	$4.55	$3.16 ▼ $10.99	$261.33M	1.5	950,990 shs	357,674 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-15.63%	-51.57%	-54.62%	-31.65%
GLSI Greenwich LifeSciences	0.00%	-4.05%	+16.27%	-21.63%	+75.19%
IVVD Invivyd	0.00%	+23.69%	-3.14%	-1.01%	-16.59%
LXEO Lexeo Therapeutics	0.00%	-21.19%	-31.89%	-31.19%	-51.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.09 +0.5%	$2.02	$1.05 ▼ $3.82	$68.32M	-0.23	493,671 shs	659,250 shs
GLSI Greenwich LifeSciences	$18.72 +2.7%	$15.84	$7.78 ▼ $34.10	$274.81M	1.47	217,639 shs	31,492 shs
IVVD Invivyd	$0.97 +3.5%	$0.78	$0.53 ▼ $3.07	$287.98M	0.81	3.76 million shs	3.73 million shs
LXEO Lexeo Therapeutics	$3.18 -3.8%	$4.55	$3.16 ▼ $10.99	$261.33M	1.5	950,990 shs	357,674 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-15.63%	-51.57%	-54.62%	-31.65%
GLSI Greenwich LifeSciences	0.00%	-4.05%	+16.27%	-21.63%	+75.19%
IVVD Invivyd	0.00%	+23.69%	-3.14%	-1.01%	-16.59%
LXEO Lexeo Therapeutics	0.00%	-21.19%	-31.89%	-31.19%	-51.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$6.86	529.10% Upside
GLSI Greenwich LifeSciences	2.00	Hold	$69.00	266.85% Upside
IVVD Invivyd	2.33	Hold	$8.00	710.54% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$18.13	465.52% Upside

Current Analyst Ratings Breakdown

Latest CNTB, GLSI, IVVD, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	GLSI Greenwich LifeSciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/23/2026	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
9/22/2026	LXEO Lexeo Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/22/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$5.00
9/16/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
9/15/2026	CNTB Connect Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/14/2026	IVVD Invivyd	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	1,143.96	N/A	N/A	$0.75 per share	1.45
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	$0.03 per share	N/A
IVVD Invivyd	$53.43M	5.45	N/A	N/A	$1.04 per share	0.95
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
GLSI Greenwich LifeSciences	-$19.36M	-$1.54	N/A	N/A	N/A	N/A	-793.81%	-295.32%	11/13/2026 (Estimated)
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	12/14/2026 (Estimated)

Latest CNTB, GLSI, IVVD, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/11/2026	Q2 2026	GLSI Greenwich LifeSciences	-$0.33	-$0.27	+$0.06	-$0.27	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
GLSI Greenwich LifeSciences	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
GLSI Greenwich LifeSciences	N/A	1.54	1.54
IVVD Invivyd	N/A	5.87	5.87
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
GLSI Greenwich LifeSciences	4.16%
IVVD Invivyd	70.36%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
GLSI Greenwich LifeSciences	51.47%
IVVD Invivyd	12.25%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	64	62.97 million	48.74 million	Optionable
GLSI Greenwich LifeSciences	13	14.68 million	7.12 million	Not Optionable
IVVD Invivyd	122	294.76 million	258.65 million	Optionable
LXEO Lexeo Therapeutics	59	82.05 million	80.41 million	Not Optionable

CNTB, GLSI, IVVD, and LXEO Headlines

Recent News About These Companies

Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

September 26 at 7:55 AM | theglobeandmail.com

Lexeo Therapeutics (NASDAQ:LXEO) Earns Outperform Rating from Leerink Partners

September 25 at 1:42 AM | americanbankingnews.com

Lexeo to acquire Mantle Therapeutics

September 24, 2026 | thepharmaletter.comT

Leerink Partners Reaffirms "Outperform" Rating for Lexeo Therapeutics (NASDAQ:LXEO)

September 23, 2026 | marketbeat.com

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

September 23, 2026 | prnewswire.com

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

September 23, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million .

September 22, 2026 | marketscreener.comM

Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research Collaborations

September 22, 2026 | finance.yahoo.com

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

September 22, 2026 | rttnews.com

Lexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations

September 22, 2026 | rttnews.com

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

September 22, 2026 | seekingalpha.com

Lexeo Therapeutics expands FA pipeline with Mantle acquisition

September 22, 2026 | tipranks.com

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

September 22, 2026 | globenewswire.com

Lexeo Therapeutics (NASDAQ:LXEO) Upgraded to Sell at Wall Street Zen

September 19, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Lexeo Therapeutics (NASDAQ:LXEO) to Sell

September 19, 2026 | marketbeat.com

Frazier Life Sciences Management L.P. Grows Stock Holdings in Lexeo Therapeutics, Inc. $LXEO

September 7, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of "Buy" by Analysts

September 4, 2026 | marketbeat.com

BlackRock Inc. Takes Position in Lexeo Therapeutics, Inc. $LXEO

September 3, 2026 | marketbeat.com

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

September 2, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. $LXEO Shares Acquired by Montanova Capital LLC

September 1, 2026 | marketbeat.com

Bank of America Corp DE Increases Position in Lexeo Therapeutics, Inc. $LXEO

September 1, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CNTB, GLSI, IVVD, and LXEO Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.08 +0.01 (+0.46%)

As of 01:06 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Greenwich LifeSciences NASDAQ:GLSI

$18.72 +0.50 (+2.74%)

As of 01:04 PM Eastern

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Invivyd NASDAQ:IVVD

$0.97 +0.03 (+3.62%)

As of 01:06 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Lexeo Therapeutics NASDAQ:LXEO

$3.22 -0.10 (-2.87%)

As of 01:06 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, GLSI, IVVD, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, GLSI, IVVD, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, GLSI, IVVD, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTB, GLSI, IVVD, and LXEO Company Descriptions

Connect Biopharma NASDAQ:CNTB

Greenwich LifeSciences NASDAQ:GLSI

Invivyd NASDAQ:IVVD

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CNTB, GLSI, IVVD, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CNTB, GLSI, IVVD, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CNTB, GLSI, IVVD, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CNTB, GLSI, IVVD, and LXEO Company Descriptions

Connect Biopharma NASDAQ:CNTB

Greenwich LifeSciences NASDAQ:GLSI

Invivyd NASDAQ:IVVD

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools